Jobs
-
Altamira Therapeutics announced that a private investor has acquired a 51% stake in Altamira Medica, a subsidiary of Altamira that owns Bentrio bentonite nasal spray, which is sold over the counter for the treatment of… Read more . . .
-
Australian CDMO Ab Initio Pharma has announced the opening of a new R&D facility in Sydney, which the company says is “fitted out to provide state-of-the-art testing and R&D services to Australian and overseas companies… Read more . . .
-
Inhalon Biopharma has announced that the company received a $5.7 million contract from the United States Army Medical Research and Development Command (USAMRDC) for development of a nebulized therapy against all variants of SARS-CoV-2. The… Read more . . .
-
Viatris and Theravance Biopharma say that a Phase 3 trial of Yupelri revefenacin inhalation solution for the treatment of COPD conducted in China met its primary endpoint and that Viatris expects to file a marketing application… Read more . . .
-
Milestone Pharmaceuticals has published data from the Phase 2 ReVeRA trial of etripamil nasal spray in patients experiencing atrial fibrillation with rapid ventricular rate (AFib-RVR) that the company says “support further development of self-administered etripamil… Read more . . .
-
Altamira Therapeutics (formerly Auris Medical) said that the European Patent Office (EPO) has issued a notice that it will grant a patent (No. 3698791) covering the company’s AM-125 intranasal formulation of betahistine until February 2038.… Read more . . .
-
OINDP testing specialists Copley Scientific have launched new versions of their Vertus automated shake and fire system for testing of MDIs and nasal sprays. According to Copley, the Vertus III+ is “comprehensively updated to meet testing requirements… Read more . . .
-
TFF Pharmaceuticals has published a paper on bioRxiv titled “Feasibility of Intranasal Delivery of Thin-film Freeze-dried Monoclonal Antibodies” describing characterization and deposition studies of TFF’s dry powder AUG-3387 mAbs delivered by Aptar Pharma‘s Unidose (UDS)… Read more . . .
-
The United States Federal Trade Commission (FTC) announced that it has challenged the Orange Book listings of more than 100 patents related to combination products, with most of those patents related to inhaler device components… Read more . . .
-
After recently raising $175 million for continued development of AP01 inhaled pirfenidone and AP02 inhaled nintedanib, Avalyn Pharma has announced four new executive hires. The new appointments include former Boehringer Ingelheim interstitial lung disease (ILD)… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.